Cargando…

Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study

AIM: A metabolomics approach has recently been used to identify metabolites associated with response to antipsychotic treatment. This study was designed to identify the predictive biomarkers of response to olanzapine monotherapy using a metabolomics‐based strategy. METHODS: Twenty‐five first‐episode...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Xiaoni, Xu, Jing, Xiu, Meihong, Li, Xirong, Liu, Haixia, Wu, Fengchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437236/ https://www.ncbi.nlm.nih.gov/pubmed/35769008 http://dx.doi.org/10.1111/cns.13895

Ejemplares similares

Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia
por: Liu, Jiahong, et al.
Publicado: (2021)

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study
por: Zhao, Lei, et al.
Publicado: (2023)

Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Kynurenine pathway metabolites are associated with gray matter volume in subjects with schizophrenia
por: Zhou, Sumiao, et al.
Publicado: (2022)

A pilot study to examine the association between COX-2 rs5275 polymorphism and the response to repetitive transcranial stimulation in schizophrenia
por: Wang, Pingping, et al.
Publicado: (2023)

Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Kynurenine pathway metabolites in migraine
por: Nicoletti, Ferdinando
Publicado: (2015)

Imbalanced Kynurenine Pathway in Schizophrenia
por: Kegel, Magdalena E, et al.
Publicado: (2014)

Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study
por: Chen, Xiaofang, et al.
Publicado: (2023)

Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study
por: Wu, Zhiwei, et al.
Publicado: (2021)

Effects of low-dose combined olanzapine and sertraline on negative and depressive symptoms in treatment-resistant outpatients with acute exacerbated schizophrenia
por: Lang, Xiaoe, et al.
Publicado: (2023)

Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease
por: Liang, Yuqing, et al.
Publicado: (2022)

Kynurenine Metabolites and Migraine: Experimental Studies and Therapeutic Perspectives
por: Fejes, Annamária, et al.
Publicado: (2011)

Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
por: Chen, Yiquan, et al.
Publicado: (2009)

O066. Kynurenine pathway metabolites in cluster headache
por: Curto, Martina, et al.
Publicado: (2015)

Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis
por: Tan, Vanessa X., et al.
Publicado: (2019)

Electrochemical Determination of Kynurenine Pathway Metabolites—Challenges and Perspectives
por: Sadok, Ilona, et al.
Publicado: (2021)

Early Life Stress and the Fate of Kynurenine Pathway Metabolites
por: Coplan, Jeremy D., et al.
Publicado: (2021)

Measurement of kynurenine pathway metabolites by tandem mass spectrometry
por: Abusoglu, Sedat, et al.
Publicado: (2023)

Kynurenine Pathway Metabolites as Potential Biomarkers in Chronic Pain
por: Auyeung, Andrew, et al.
Publicado: (2023)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang, Fuyin, et al.
Publicado: (2018)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Toxoplasma gondii Effects on the Relationship of Kynurenine Pathway Metabolites to Acoustic Startle Latency in Schizophrenia vs. Control Subjects
por: Pearce, Bradley D., et al.
Publicado: (2020)

Altered kynurenine pathway metabolites in serum of chronic migraine patients
por: Curto, Martina, et al.
Publicado: (2016)

The impact of bariatric surgery on serum tryptophan–kynurenine pathway metabolites
por: Yeung, Kai Tai Derek, et al.
Publicado: (2022)

Dietary Kynurenine Pathway Metabolites—Source, Fate, and Chromatographic Determinations
por: Sadok, Ilona, et al.
Publicado: (2023)

Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine
por: Koola, Maju Mathew
Publicado: (2016)

Effects of inflammation on the kynurenine pathway in schizophrenia — a systematic review
por: Pedraz-Petrozzi, Bruno, et al.
Publicado: (2020)

Potential drug targets in the kynurenine pathway to treat acute schizophrenia
por: Malhotra, Ayush, et al.
Publicado: (2021)

Clinical predictors of kynurenine pathway aberrations in schizophrenia and bipolar disorder
por: Skorobogatov, K., et al.
Publicado: (2022)

Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia
por: Tsuneyama, Nobuto, et al.
Publicado: (2016)

Genetic polymorphisms of BDNF on cognitive functions in drug-naive first episode patients with schizophrenia
por: Su, Xiuru, et al.
Publicado: (2021)

Associations of the serum kynurenine pathway metabolites with P50 auditory gating in non-smoking patients with first-episode schizophrenia
por: Yang, Qingyan, et al.
Publicado: (2022)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors
por: Hughes, Tamera D., et al.
Publicado: (2022)

Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway
por: Tanaka, Masaru, et al.
Publicado: (2021)

Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease
por: Gáspár, Renáta, et al.
Publicado: (2022)

Kynurenine Pathway Metabolites in the Blood and Cerebrospinal Fluid Are Associated with Human Aging
por: Solvang, Stein-Erik H., et al.
Publicado: (2022)

A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia
por: Büki, Alexandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9pmmla1ac1imknd3qt7tnm2s2d